Trial Profile
A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2014
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record